ALK and adenocarcinoma: The diagnosis of adenocarcinoma (epidermal growth factor receptor (EGFR) mutation exon 19 deletion, programmed death ligand 1 (PD-L1) <1%, c-ros oncogene (ROS1) negative, anaplastic lymphoma kinase (ALK) negative) was established through pleural fluid cytology and bronchoscopy.